Can An Antibody Cocktail Block COVID-19 Infection? Regeneron’s Warp Speed Research Aims To Find Out Soon

Could Be Available In Late Summer

The only non-vaccine project backed by Operation Warp Speed, Regeneron’s antibody cocktail could play a crucial role in the fight against SARS-CoV2 – if it works. Clinical development chief David Weinreich talks to Scrip about its innovative adaptive trial collaboration, and how it could provide answers in a matter of months.

Covid19_Blood_Samples

While each day brings fresh updates on the progress of companies developing vaccines to fight COVID-19, which are rightly seen as the most powerful weapon against the novel coronavirus, the potential of novel antibody cocktails is also being explored at pace by biopharma companies, government and academic researchers.

The promise is that a mix of two or more antibodies, either discovered in the lab or based on antibodies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D